Influenza Vaccine Market Size & Share, by Type (Quadrivalent, Trivalent); Technology (Egg-based, Cell Culture); Age Group (Pediatric, Adult); Route of Administration (Injection, Nasal Spray); End-user (Hospitals, Pharmacies, Government Vaccination Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 153
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Influenza Vaccine Market size is poised to reach USD 13.8 Billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023-2035. In the year 2023, the industry size of influenza vaccine was over USD 6 Billion. The growth of the market can be primarily attributed to the rising cases of influenza coupled with the continuous evolution of the variety of influenza viruses around the world, increasing the incidence of influenza epidemics and seasonal changes. According to the World Health Organization, the influenza virus remains a major public health challenge around the world. Globally, 1 billion influenza cases occur every year, 3 to 5 million of which are severe, leading to 290 000 to 650 000 deaths from influenza-related respiratory diseases.

Furthermore, the increasing number of clinical trials for new products increased vaccinations, the rapid spread of communicable diseases along with rising healthcare spending is projected to drive the global market growth during the forecast period. According to the data released by the Centers for Medicare & Medicaid Services, healthcare spending in the United States in 2020 exceeded USD 4.1 trillion, equivalent to 19.7% of GDP. Besides, the increasing use of vaccines during COVID-19 and increasing vaccination programs in developing countries are estimated to boost market growth.


Influenza-Vaccine-Market
Get more information on this report: Request Free Sample PDF

Influenza Vaccine Sector: Growth Drivers and Challenges

Growth Drivers

  • Positive Impact of Influenza Vaccine on COVID -19 Patients - It was observed that in 2021, nearly 74,000 COVID-19 patients globally were given shots of the influenza vaccine, which reduced strokes, sepsis, and deep vein thrombosis among patients.
  • The increasing incidence of the COVID-19 virus is resulting in a surge in demand for influenza vaccines. As a result of the influenza vaccine, COVID-19 will not be prevented from spreading but instead result in a reduction in illness, deaths, and hospitalizations. Therefore, COVID-19 outbreaks and a continuous rise in COVID-19 cases are expected to enlarge the global market size during the forecast period.
  • Initiatives By WHO, such as the Global Influenza Program- World Health Organization has collaborated with scientists and authorities on a global scale for more than 50 years to develop influenza vaccines. In February and September, it holds expert consultations to determine which viruses should be included in the seasonal influenza vaccine.
  • Increasing Research and Development Initiatives by the Government - The World Bank reports that there were 1,597 researchers per million in 2018 compared to 14,12 researchers in 2015. 
  • Rising Prevalence of Chronic Diseases Worldwide Rising the Vaccines Demand- According to the Centers for Disease Control and Prevention, 2018, there were 51.8% of US adults with at least one chronic condition in 2018, and the percentage of people with multiple chronic conditions was 27.2%.
  • Campaigns to Increase Awareness of Influenza Vaccines Among the People – For instance, in 2021, the Minister’s Department of Health and Aged Care of Australia announced the official launch of the National Flu Vaccination Program aiming to make the vaccine accessible to everyone. A total of 5 million Australian people has already been vaccinated against the flu for 2021.

Challenges

  • Low Vaccination Awareness in Developing Countries 
  • Complex and Time-Consuming Process Involved in Vaccine Production- It takes 10-15 years for a single vaccine to develop into a safe, quality, and efficacy product. The development procedure includes vaccine research, clinical development, and regulatory requirements which take a long time. Also, the regulatory frameworks for clinical trials are different in various regions which takes time for the clearing process. All the factors are estimated to hinder market growth.
  • High Cost Associated with the Vaccine

Influenza Vaccine Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

7%

Base Year Market Size (2023)

USD 6 Billion

Forecast Year Market Size (2035)

  USD 13.8 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Influenza Vaccine Segmentation

Age Group (Pediatric, Adult)

The global market is segmented and analyzed for demand and supply by age group into paediatric and adult. Among these segments, the paediatric segment is anticipated to capture the largest market size in the global influenza vaccine market owing to the higher burden of flu among children aged below 5 years old. Centers for Disease Control and Prevention reports that in 2021 children younger than 5 years old were affected by 44% of flu cases. A total of 56% of deaths among children aged 5-17 were caused by the flu. Moreover, the increasing awareness among parents about safeguarding their children against infectious diseases, such as influenza coupled with children's weak immune systems is anticipated to augment segment growth during the forecast period. 

Our in-depth analysis of the global market includes the following segments:

       By Type

  • Quadrivalent
  • Trivalent

       By Technology

  • Egg-based
  • Cell Culture

        By Age Group

  • Pediatric
  •  Adult

        By Route of Administration

  • Injection
  • Nasal Spray

         By End User

  • Hospitals
  • Pharmacies
  • Government Vaccination Centers

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Influenza Vaccine Industry - Regional Synopsis

The region influenza vaccine market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The rapid spread of the influenza A virus among the population, new product launches, and expansion of services for product distribution. As per the data by CDC, in 2022, the United States reported seven cases of human infections with novel variants of influenza A viruses. This included 3 H3N2v and 4 H1N2v viruses. Moreover, the development of innovative products and increasing initiatives towards influenza vaccination coupled with the advanced technological vaccine manufacturing process in North America is anticipated to drive the regional market in the coming years. 

Get more information on this report: Request Free Sample PDF

Companies Dominating the Influenza Vaccine Market

top-features-companies
    • BioDiem Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • SANOFI
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Sinovac Biotech Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Emergent BioSolutions Inc.
    • CSL Limited
    • Johnson & Johnson Services, Inc.
    • Astellas Pharma Inc.

In the News

  • SANOFI acquired Transcript Bio for the purpose of deploying mRNA technology in vaccine development as well as therapeutic development. 

  • BioDiem Ltd. announced the approval of Changchun BCHT Biotechnology Co ("BCHT") as their licensee in China. A live, nasal, freeze-dried influenza vaccine was launched by BCHT in August 2020 in China.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 153
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rapid spread of influenza virus, rising COVID-19 cases, increasing healthcare spending along with incidence of chronic diseases among people are the major factors driving the growth of the influenza vaccine market.

The market is anticipated to attain a CAGR of 7 over the forecast period, i.e., 2023-2035.

Low vaccination awareness in developing countries and complex process in development of vaccines are the challenges affecting the market growth

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Sanofi-aventis Groupe, Sinovac Biotech Ltd., Serum Institute of India Pvt. Ltd., Emergent BioSolutions Inc., CSL Limited, Johnson & Johnson Services, Inc. and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, technology, age group, route of administration, end user, and by region.

The pediatric segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Influenza Vaccine Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying